The Drug Hunter’s Assistant: Accelerating Drug Discovery With AI

Are The High Expectations Justified?

The hype around Artificial Intelligence has been deafening in recent years, but real progress can only come when drug discovery culture and regulators catch up with the technology.

IV1912_AI_Machine_learning_1096541144_1200.jpg
Millions of dollars have been poured into AI-based drug discovery start-ups in the US, Europe and beyond • Source: Shutterstock

Excitement about the potential of artificial intelligence (AI) to transform drug discovery has been building for several years. Millions of dollars have been poured into AI-based drug discovery start-ups in the US, Europe and beyond, who are all racing to reach the first true proof-of-concept for the approach.

Big pharma has also been investing in the field, both internally and in partnership with new AI-focused platforms. There is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Outlook Archive

Big Three Lead From The Front With Medtech Back On Solid Growth Footing

 
• By 

Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.  

Infographic: Top 100 Pharma Companies

 

The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.    

Pfizer Leads An Unusual Year For The Scrip 100

 

Pfizer catapulted back into the lead in the pharmaceutical rankings on the strength of COVID-19 revenues while BioNTech and Moderna both made the list for the first time.      

Outlook 2023: The Pharma Rollercoaster Shows No Signs Of Slowing Down

 
• By 

What will 2023 bring as the industry faces one of the toughest periods in the last decade? In Vivo asked three industry experts for their views.

More from Outlook

Legal Challenges Mount Over Germany’s Controversial Combination Rebate

 

The pharmaceutical industry has been pushing back on a deeply unpopular rebate on products deemed to be “free combination” medicines in Germany.

Celltrion USA’s New CMO Champions Regulatory Reform And Access

 
• By 

Juby Jacob-Nara outlines her vision for expanding biosimilar uptake and leveraging policy changes to improve patient access.

Small Biotech, Big Breakthrough: Abivax Enters A New Era

 

Abivax reflects on a transformative year marked by landmark clinical success and ambitious plans for the future.